Condition 1: type 2 diabetes. Condition 2: obesity. Non-insulin-dependent diabetes mellitus obesity
Conditions
Interventions
Intervention 1: Placebo (Paraffin): 3 Soft Gel (1 gr each) with Meals of Breakfast, Lunch and Dinner for 8 weeks. Intervention 2: 3 pomegranate seed oil soft gels (1 gr each) with Meals of Breakfast,
Placebo
Treatment - Drugs
Placebo (Paraffin): 3 Soft Gel (1 gr each) with Meals of Breakfast, Lunch and Dinner for 8 weeks
3 pomegranate seed oil soft gels (1 gr each) with Meals of Breakfast, Lunch and Dinner daily for 8 weeks
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 50 Years
Inclusion criteria
Inclusion criteria: ?Age between 30 to 50 years BMI greater than 30 and less than 40 Fasting glucose equal to or greater than 126 Having a willingness and ability to cooperate in the study
Exclusion criteria
Exclusion criteria: Pregnant women Lactating women, Patients under hormone therapy Patients who taking TZD or Insulin medications Patients who taking lipid-lowering medications Patients who taking weight loss medications Patients who didn't take antioxidants drugs (at least 3 months ago) Patients with impaired fat metabolism Patients who have allergies to pomegranate Patients who consumed less than 90% of pomegranate seed oil, changed their dose of medicine Patients who taking vitamins (D, A, B6), and omega 3 supplements Patients who do not have the desire or ability to continue studying
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting insulin. Timepoint: Before and the end of the intervention (eighth week). Method of measurement: Autoanalyzer kit.;Hemoglobin A1C. Timepoint: Before and the end of the intervention (eighth week). Method of measurement: Autoanalyzer kit.;High- sensitive C-reactive protein of Serum. Timepoint: Before and the end of the intervention (eighth week). Method of measurement: ELISA.;Serum interleukin-6. Timepoint: Before and the end of the intervention (eighth week). Method of measurement: ELISA.;Serum tumor necrosis factor-alpha. Timepoint: Before and the end of the intervention (eighth week). Method of measurement: ELISA.;Glucose transporter type 4 gene expression. Timepoint: Before and the end of the intervention (eighth week). Method of measurement: Real time PCR.;Peroxisome proliferator-activated receptors gamma gene expression. Timepoint: Before and the end of the intervention (eighth week). Method of measurement: Real time PCR.;Serum triglycerides. Timepoint: Before and the end of the intervention (eighth week). Method of measurement: Autoanalyzer kit.;Serum low density lipoprotein cholesterol. Timepoint: Before and the end of the intervention (eighth week). Method of measurement: Autoanalyzer kit.;Serum high density lipoprotein cholesterol. Timepoint: Before and the end of the intervention (eighth week). Method of measurement: Autoanalyzer kit.;Total cholesterol. Timepoint: Before and the end of the intervention (eighth week). Method of measurement: Autoanalyzer kit.;Fasting blood glucose. Timepoint: Before and the end of the intervention (eighth week). Method of measurement: Autoanalyzer kit.;Insulin resistance. Timepoint: Before and the end of the intervention (eighth week). Method of measurement: Homeostasis model (HOMA-IR).;Insulin sensitivity. Timepoint: Before and the end of the intervention (eighth week). Method of measurement: QUICKI. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body mass index. Timepoint: Before and at the end of the intervention (eighth week). Method of measurement: the body mass divided by the square of the body height.;Fat mass. Timepoint: Before and at the end of the intervention (eighth week). Method of measurement: bioelectrical impedance. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactYaser khajebishak
Faculty of Nutrition and Food Sciences
Outcome results
None listed